Dr. James E. Hoffman, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 404
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME104429 -
Internal Medicine Physician
FL license ME104429
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 404
- Services billed
- 1,395
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 739 | 285 |
| Established patient office or other outpatient visit, 30-39 minutes | 114 | 78 |
| New patient office or other outpatient visit, 60-74 minutes | 59 | 59 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Miami, FL | 153 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Miami, FL | 40 |
| Dexamethasone Other prescribers in Miami, FL | 24 |
| Xarelto (rivaroxaban) Other prescribers in Miami, FL | 22 |
| Oxycodone Hcl Other prescribers in Miami, FL | 20 |
| Colestipol Hcl Other prescribers in Miami, FL | 19 |
| Gabapentin Other prescribers in Miami, FL | 15 |
| Alprazolam Other prescribers in Miami, FL | 14 |
| Ondansetron Hcl Other prescribers in Miami, FL | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $6,661 in total to this clinician.
| GlaxoSmithKline, LLC. | $6,172 |
|---|---|
| Pfizer Inc. | $189 |
| Janssen Scientific Affairs, LLC | $150 |
| Janssen Biotech, Inc. | $64.97 |
| Celgene Corporation | $38.92 |
| Legend Biotech USA Inc. | $31.98 |
| AstraZeneca Pharmaceuticals LP | $14.45 |
| Consulting Fee | $6,125 |
|---|---|
| Travel and Lodging | $372 |
| Food and Beverage | $132 |
| Education | $31.98 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Jul 24, 2025 | Consulting Fee BLENREP · ONCOLOGY | $5,800 |
| GlaxoSmithKline, LLC. Jul 14, 2025 | Travel and Lodging BLENREP · ONCOLOGY · travel to Lake Buena Vista, FL | $372 |
| Pfizer Inc. Jul 2, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $175 |
| Janssen Scientific Affairs, LLC Jul 11, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Legend Biotech USA Inc. Dec 15, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
| Legend Biotech USA Inc. Aug 11, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $80,143 in research payments for these studies, mostly to the institutions running them.
- Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03761108 - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
AbbVie Inc. · Recruiting · NCT06158854 - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.